Genetic study to guide antiarrhythmic drugs for atrial fibrillation
Treatments studied
Part of Heart & circulation clinical trials.
This study looks at how a person’s genetics may affect how well and safely antiarrhythmic medicines work for atrial fibrillation (AF). If you join, you may get medicine options like flecainide or sotalol, and researchers compare outcomes to genetic information.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and can sign informed consent
- You have AF that comes and goes or lasts (paroxysmal or persistent) and causes symptoms
- You’ve had AF symptoms at least 2 times per month
- Your heart tracing (ECG) was done within 1 month showing AF
- Your clinician says you can take both flecainide and sotalol for AF
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at early changes in the heart related to atrial fibrillation (AF) using health data and biomarkers. It aims to find better ways to predict or understand AF, especially around procedures like ablation or cardioversion.
This study tests a stepwise treatment plan for people with persistent atrial fibrillation (a long-lasting irregular heartbeat) who also have an enlarged left atrium. It aims to see if a medication called amiodarone plus a cardioversion procedure can help restore normal rhythm.
This trial studies abnormal electrical signals in the right upper heart chamber and how they relate to atrial fibrillation (AF). It may help improve how doctors target AF treatment during catheter ablation for people who have AF symptoms.
This study looks at the risk of a fast heart rhythm (ventricular tachycardia) in people with genetic heart muscle diseases. It tests whether having a specific genetic change affects the success of a heart ablation procedure.
This trial looks at whether certain blood markers and genetic information can help predict atrial fibrillation (irregular heartbeat). It studies how inflammation might play a role, and aims to find better ways to identify people at risk.
This study looks at how to better predict both stroke risk and bleeding risk in people with atrial fibrillation. It may help doctors choose safer blood-thinner treatment and follow-up plans.
Hear when a new Atrial fibrillation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.